Cannenta has signed a Heads of Agreement with Nexgel Inc

Cannenta has signed a Heads of Agreement with US based manufacturer, Nexgel Inc. for the supply of wound dressings under contract for Cannenta.

Initially, Nexgel will be providing quantities of their electron-beam crosslinked polymer hydrogels containing Cannenta’s unique factor, 2dDR for use in preclinical and clinical trials.

Nexgel is one of only a few providers who can produce hydrogel patches using the e-beam technology, which avoids the need for chemical cross-linking agents.

“Nexgel is a great manufacturing partner for us” said Iain Ralph, Chief Executive of Cannenta.  “They are an experienced manufacturer of medical hydrogel products and have a history of working with early-stage ventures through development, preclinical and clinical programs.   They have production capacity to supply substantial volumes when our product is ready for market release.

“We are also pleased with the flexibility they have shown in working with us to date and look forward to furthering this constructive relationship.”

Cannenta is a private company in Melbourne Australia developing wound dressing products containing 2-deoxy-D-ribose (2dDR), a compound which has been shown to significantly improve wound bed vascularisation in laboratory and animal trials.   Cannenta will be targeting chronic wound applications including diabetic foot ulcers with a range of wound care products incorporating 2dDR and is soon to commence clinical program with first products.

Nexgel is a public company listed on NASDAQ, headed by CEO Adam Levy and based in Pennsylvania US.  They develop and manufacture a range of hydrogel sheet products for cosmetic and medical applications.

For more information contact:  enquiries@cannenta.com